New Rare Disease Center of Excellence and FDA Advances in Rare Disease

In a recent episode of The CheckRare Brief, Eugene Lee, Group President, Specialty Communications at CMI Media Group, discussed how rapid shifts in the rare disease landscape are redefining pharmaceutical commercialization and trial design. Highlighting recent FDA regulatory milestones—including the landmark approval of a generic radioligand therapy for neuroendocrine tumors and progressive new guidelines that shorten rare disease trial recruitment—Lee outlined why traditional, broad-scale marketing models are giving way to micro-precision targeting. Underscoring the launch of CMI Media Group’s dedicated Rare Disease Center of Excellence, Lee emphasized that reaching low-incidence patient populations requires advanced data signals, specialized HCP pathway mapping, and real-world evidence integration to accelerate diagnosis and ensure life-changing therapies reach the right patients faster. 

Read the full article and watch the podcast episode here.